Biovica: FDA approval in sight - Redeye

Redeye's Q1 conclusion is that the US DiviTum approval is on track and that a decision is likely in September alternatively after addressing a potential request for additional information. This is the most important Q1 feedback. We expect value support as a result of this information and clarification. Our value proposition is a base case value of SEK 95 (Bull SEK 325 and Bear SEK 20).

Länk till analysen i sin helhet: https://www.redeye.se/research/819922/biovica-q1-fda-approval-in-sight?utm_source=finwire&utm_medium=RSS